Biogen Inc. (ETR: IDP)

Market Cap	20.49B
Revenue (ttm)	8.61B
Net Income (ttm)	1.45B
Shares Out	n/a
EPS (ttm)	9.92
PE Ratio	14.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Open	141.85
Previous Close	144.05
Day's Range	141.85 - 141.85
52-Week Range	141.50 - 245.60
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 13, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab bio...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,570
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: IDP

Financial Performance

In 2023, Biogen's revenue was $9.84 billion, a decrease of -3.32% compared to the previous year's $10.17 billion. Earnings were $1.16 billion, a decrease of -61.89%.

Financial numbers in USD